JP2011520921A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011520921A5 JP2011520921A5 JP2011509790A JP2011509790A JP2011520921A5 JP 2011520921 A5 JP2011520921 A5 JP 2011520921A5 JP 2011509790 A JP2011509790 A JP 2011509790A JP 2011509790 A JP2011509790 A JP 2011509790A JP 2011520921 A5 JP2011520921 A5 JP 2011520921A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- cancer
- inhibitor
- anticancer drug
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US5372608P | 2008-05-16 | 2008-05-16 | |
| US61/053,726 | 2008-05-16 | ||
| PCT/US2009/044334 WO2009140675A2 (en) | 2008-05-16 | 2009-05-18 | Combination therapy with an antitumor alkaloid |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2011520921A JP2011520921A (ja) | 2011-07-21 |
| JP2011520921A5 true JP2011520921A5 (enExample) | 2012-07-05 |
Family
ID=41136781
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011509790A Pending JP2011520921A (ja) | 2008-05-16 | 2009-05-18 | 抗腫瘍アルカロイドとの併用療法 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20110070232A1 (enExample) |
| EP (1) | EP2307003A2 (enExample) |
| JP (1) | JP2011520921A (enExample) |
| KR (1) | KR20110025178A (enExample) |
| CN (1) | CN102099025A (enExample) |
| AU (1) | AU2009246130A1 (enExample) |
| CA (1) | CA2724325A1 (enExample) |
| IL (1) | IL209361A0 (enExample) |
| MX (1) | MX2010012501A (enExample) |
| NZ (1) | NZ589269A (enExample) |
| RU (1) | RU2010151602A (enExample) |
| WO (1) | WO2009140675A2 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7919493B2 (en) | 2000-04-12 | 2011-04-05 | Pharma Mar, S.A. | Anititumoral ecteinascidin derivatives |
| MXPA02011319A (es) | 2000-05-15 | 2003-06-06 | Pharma Mar Sa | Analogos antitumorales de ecteinascidina 743. |
| GB0117402D0 (en) | 2001-07-17 | 2001-09-05 | Pharma Mar Sa | New antitumoral derivatives of et-743 |
| GB0202544D0 (en) | 2002-02-04 | 2002-03-20 | Pharma Mar Sa | The synthesis of naturally occuring ecteinascidins and related compounds |
| WO2011048210A1 (en) | 2009-10-22 | 2011-04-28 | Pharma Mar, S.A. | PDGFR-α AS RESPONSE MARKER FOR PM00104 TREATMENT |
| CA2995033C (en) * | 2010-11-12 | 2020-04-28 | Pharma Mar, S.A. | Combination therapy with an antitumor alkaloid |
| US9192609B2 (en) | 2013-04-17 | 2015-11-24 | Hedgepath Pharmaceuticals, Inc. | Treatment and prognostic monitoring of proliferation disorders using hedgehog pathway inhibitors |
| CN120661674A (zh) | 2016-03-15 | 2025-09-19 | 奥莱松基因组股份有限公司 | 用于治疗实体瘤的lsd1抑制剂的组合 |
| TWI807411B (zh) | 2017-04-27 | 2023-07-01 | 西班牙商瑪製藥股份有限公司 | 抗腫瘤化合物 |
| KR102260846B1 (ko) * | 2018-07-09 | 2021-06-07 | 국립암센터 | 고시폴, 펜포르민 및 항암제를 포함하는 암 예방 또는 치료용 약학적 조성물 |
| EP4061372A1 (en) | 2019-11-21 | 2022-09-28 | Pharma Mar, S.A. | Methods of treating small cell lung cancer with lurbinectedin formulations |
| US12441707B2 (en) | 2019-12-30 | 2025-10-14 | Tyra Biosciences, Inc. | Indazole compounds |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2245165A1 (en) * | 1996-01-31 | 1997-08-07 | Mien-Chie Hung | Sensitization of her2/neu over-expressing cancer cells to chemotherapeutic drugs |
| SK284511B6 (sk) * | 1997-07-29 | 2005-05-05 | Pharmacia & Upjohn Company | Samoemulgujúce formulácie pre lipofilné zlúčeniny |
| US6350479B1 (en) * | 1998-06-05 | 2002-02-26 | Regent Court Technologies | Treating depression with alcohol extracts of tobacco |
| US6124292A (en) * | 1998-09-30 | 2000-09-26 | President And Fellows Of Harvard College | Synthetic analogs of ecteinascidin-743 |
| AR035842A1 (es) * | 1999-05-14 | 2004-07-21 | Pharma Mar Sa | Metodo de hemisintesis para la formacion de compuestos intermediarios y derivados y de estructuras relacionadas con la ecteinascidina y de tetrahidroisoquinolinfenoles y compuestos intermediarios de aplicacion en dicho metodo |
| JP2003520801A (ja) * | 2000-01-19 | 2003-07-08 | ザ・トラスティーズ・オブ・コランビア・ユニバーシティー・イン・ザ・シティー・オブ・ニューヨーク | サフラマイシン−エクテイナシジン系列の化合物、それらの使用及び合成 |
| MXPA02011319A (es) * | 2000-05-15 | 2003-06-06 | Pharma Mar Sa | Analogos antitumorales de ecteinascidina 743. |
| GB0229793D0 (en) * | 2002-12-20 | 2003-01-29 | Pharma Mar Sa | The gene cluster involved in safracin biosynthesis and its uses for genetic engineering |
| WO2007008200A1 (en) * | 2004-07-09 | 2007-01-18 | Prolx Pharmaceuticals Corp. | Wortmannin analogs and methods of using same in combination with chemotherapeutic agents |
| GB0522082D0 (en) * | 2005-10-31 | 2005-12-07 | Pharma Mar Sa | Formulations |
| JP2009514889A (ja) * | 2005-11-04 | 2009-04-09 | メルク エンド カムパニー インコーポレーテッド | 癌を治療するためにｓａｈａ及びボルテゾミブを用いる方法 |
| KR101354828B1 (ko) * | 2005-11-04 | 2014-02-18 | 와이어쓰 엘엘씨 | ｍＴＯＲ 저해자, 헤르셉틴, 및/또는 ＨＫＩ-272의항신생물성 조합 |
| CA2652633C (en) * | 2006-06-21 | 2014-03-25 | Eli Lilly And Company | Crystalline forms of gemcitabine amide prodrug, compositions and use thereof |
| CN102065865B (zh) * | 2008-05-16 | 2013-03-20 | 马尔药品公司 | 多发性骨髓瘤治疗 |
-
2009
- 2009-05-18 EP EP09747756A patent/EP2307003A2/en not_active Withdrawn
- 2009-05-18 US US12/992,812 patent/US20110070232A1/en not_active Abandoned
- 2009-05-18 CN CN2009801276302A patent/CN102099025A/zh active Pending
- 2009-05-18 RU RU2010151602/15A patent/RU2010151602A/ru not_active Application Discontinuation
- 2009-05-18 NZ NZ589269A patent/NZ589269A/xx not_active IP Right Cessation
- 2009-05-18 CA CA2724325A patent/CA2724325A1/en not_active Abandoned
- 2009-05-18 AU AU2009246130A patent/AU2009246130A1/en not_active Abandoned
- 2009-05-18 KR KR1020107028378A patent/KR20110025178A/ko not_active Withdrawn
- 2009-05-18 MX MX2010012501A patent/MX2010012501A/es not_active Application Discontinuation
- 2009-05-18 JP JP2011509790A patent/JP2011520921A/ja active Pending
- 2009-05-18 WO PCT/US2009/044334 patent/WO2009140675A2/en not_active Ceased
-
2010
- 2010-11-16 IL IL209361A patent/IL209361A0/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011520921A5 (enExample) | ||
| RU2010151602A (ru) | Комбинированная терапия с помощью рм00104 и другого противоопухолевого средства | |
| JP2021169479A5 (enExample) | ||
| Oronsky et al. | What's new in SCLC? A review | |
| Monneret | Platinum anticancer drugs. From serendipity to rational design | |
| JP2013542241A5 (enExample) | ||
| Kim et al. | Second-line chemotherapy for small-cell lung cancer (SCLC) | |
| JP2020512314A5 (enExample) | ||
| JP2010520289A5 (enExample) | ||
| JP2011522773A5 (enExample) | ||
| JP2010180210A5 (enExample) | ||
| RU2013126630A (ru) | Комбинированная терапия противоопухолевым алкалоидом | |
| JP2019501873A5 (enExample) | ||
| CN102772416A (zh) | 包含GSK-3β抑制剂和SBE7-β-CD的药物组合物 | |
| NZ599878A (en) | Anticancer combination of artemisinin-based drugs and other chemotherapeutic agents | |
| JP2007277240A5 (enExample) | ||
| RU2008139406A (ru) | Комдинированная терапия (2r, z)-2-амино-2-циклогексил-n-(1-метил-1н-пиразол-4-ил)-1-оксо-2, 6-дигидо-1н-(1, 2)диазепино(4, 5, 6-d(ндол-8-ил)ацетамидом | |
| Bernal et al. | Metal-based molecules in the treatment of cancer: From bench to bedside | |
| Banik et al. | Heterocyclic anticancer agents | |
| Turek et al. | New hopes in cancer battle-a review of new molecules and treatment strategies | |
| JP2007531728A5 (enExample) | ||
| Sun et al. | Preclinical activity of lobaplatin as a single agent and in combination with taxanes for ovarian carcinoma cells | |
| Hu et al. | Current status of CPT and its analogues in the treatment of malignancies | |
| Rajput et al. | Treatment of small cell lung cancer with Lurbinectedin: a review | |
| RU2015119802A (ru) | Комбинированная терапия рака |